Delay of Otsuka's $886 Million Bid For Astex Could Draw More Suitors
This article was originally published in PharmAsia News
Otsuka Pharmaceutical's $886 million offer to acquire Astex Pharmaceuticals is set to expire Oct. 10, an event that could trigger even bigger offers from other suitors at year's end.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.